ILAE-Latin America

The ILAE - Latin America region comprises South and Middle America and Mexico where Spanish and Portuguese are the main languages spoken. Within the framework and according to the strategic plan of the central ILAE, the goal of the ILAE-Latin America is to serve as a regional resource for current and emerging knowledge on epilepsy prevention, diagnosis, treatment, and research.

Current efforts of the ILAE-Latin America are focused on the development of national epilepsy programs and laws and telemedicine projects in the region. In the field of education, courses are being organized for the primary health level as well as specialized epilepsy care.

As the region is extremely heterogeneous, an effort is being made to provide equal learning opportunities for health professionals in rich and poor countries and areas. Guidelines and seminal scientific articles that are available only in English are being translated into Spanish and Portuguese to increase access to knowledge.

Awards

Latinoamerica presente en las premiaciones del 33avo Congreso International de Epilepsia
Latin American Awards at the 33rd International Epilepsy Congress

Elections for ALADE

ILAE-Latin America announces the new members of the ALADE Task Force, effective April 2019. See Commission and Task Force Members.

Latest News

ILAE logo
About ILAE

2019 ILAE Neurobiology Commission Bursaries

The Neurobiology Commission of the ILAE is pleased to announce that the 2019 ILAE Neurobiology Commission Bursaries were awarded to the following young investigators ...

3 September, 2019
Neurology, The most widely read and highly cited peer-reviewed neurology journal
Clinical Research

Declining malformation rates with changed antiepileptic drug prescribing: An observational study

There have been major changes in AED prescription patterns over the years covered by the study. In parallel, we observed a significant 27% decrease in the prevalence of MCMs. The results of adjusting the trend analysis for MCMs for changes in AED treatment suggest that changes in prescription patterns played a major role in the reduction of teratogenic events.

27 August, 2019

View All Commission News